Also with me are David A. Santos, our Chief Commercial Officer; Lisa Rojkjaer, our Chief Medical Officer; and Dean L. Schorno, our Chief Financial Officer. On today's call, I will provide an overview ...
Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Available from Clare Instruments, the Rigel 288 medical electrical safety tester is specifically designed to enable electro-biomedical engineering departments and medical equipment service engineers ...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it ...
Zacks Investment Research on MSN
Rigel Pharmaceuticals (RIGL) earnings expected to grow: Should you buy?
Rigel Pharmaceuticals (RIGL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...
The first hand held, combination vital signs simulator capable of undertaking six synchronised vital signs parameters tests has been launched by Rigel Medical. The new Rigel UniSIM is the only ...
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $1.97 per share. This compares to a loss of $0.06 per share a year ago. These ...
(RTTNews) - Tuesday, Rigel Pharmaceuticals, Inc. (RIGL) appointed Lisa Rojkjaer, as executive vice president and chief medical officer. Rojkjaer, a board-certified hematologist with an international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results